lymphoproliferative diseases (44,9%) leukemias (all, aml, cml, mds) 33,6%

55
Lymphoproliferative diseases (44,9%) Lymphoproliferative diseases (44,9%) LEUKEMIAS (ALL, AML, CML, MDS) LEUKEMIAS (ALL, AML, CML, MDS) 33,6% 33,6% LYMPHOMAS (HD, NHL) LYMPHOMAS (HD, NHL) 9,8% 9,8% HISTIOCYTOSIS HISTIOCYTOSIS 1,5% 1,5% Solid tumours Solid tumours (55,1%) (55,1%) CNS CNS TUMOURS TUMOURS 22,7% 22,7% NEPHROBLASTOMA NEPHROBLASTOMA 6,9% 6,9% NEUROBLASTOMA NEUROBLASTOMA 6,7% 6,7% SOFT TISSUE SARCOMAS SOFT TISSUE SARCOMAS 5,9% 5,9% BONE TUMOURS (osteosarcoma, Sa. Ewing) 4,2% BONE TUMOURS (osteosarcoma, Sa. Ewing) 4,2% RETINOBLASTOMA RETINOBLASTOMA 3,3% 3,3% EMBRIONAL TUMOURS EMBRIONAL TUMOURS 2,3% 2,3% LIVER TUMOURS LIVER TUMOURS 1,0% 1,0% CARCINOMAS ADN RARE TUMOURS CARCINOMAS ADN RARE TUMOURS 2,1% 2,1%

Upload: gratia

Post on 12-Jan-2016

18 views

Category:

Documents


0 download

DESCRIPTION

Lymphoproliferative diseases (44,9%) LEUKEMIAS (ALL, AML, CML, MDS) 33,6% LYMPHOMAS (HD, NHL) 9,8% HISTIOCYTOSIS 1,5% Solid tumours (55,1%) CNSTUMOURS 22,7% - PowerPoint PPT Presentation

TRANSCRIPT

Page 1: Lymphoproliferative diseases  (44,9%) LEUKEMIAS (ALL, AML, CML, MDS)               33,6%

Lymphoproliferative diseases (44,9%)Lymphoproliferative diseases (44,9%)• LEUKEMIAS (ALL, AML, CML, MDS) 33,6%LEUKEMIAS (ALL, AML, CML, MDS) 33,6%• LYMPHOMAS (HD, NHL)LYMPHOMAS (HD, NHL) 9,8% 9,8%• HISTIOCYTOSISHISTIOCYTOSIS 1,5% 1,5%

Solid tumoursSolid tumours (55,1%)(55,1%)

• CNSCNS TUMOURS TUMOURS 22,7% 22,7%• NEPHROBLASTOMANEPHROBLASTOMA

6,9%6,9%• NEUROBLASTOMANEUROBLASTOMA

6,7%6,7%• SOFT TISSUE SARCOMASSOFT TISSUE SARCOMAS 5,9% 5,9%• BONE TUMOURS (osteosarcoma, Sa. Ewing) 4,2%BONE TUMOURS (osteosarcoma, Sa. Ewing) 4,2%• RETINOBLASTOMARETINOBLASTOMA

3,3%3,3%• EMBRIONAL TUMOURSEMBRIONAL TUMOURS

2,3%2,3%• LIVER TUMOURSLIVER TUMOURS 1,0% 1,0%• CARCINOMAS ADN RARE TUMOURS CARCINOMAS ADN RARE TUMOURS

2,1%2,1%

Page 2: Lymphoproliferative diseases  (44,9%) LEUKEMIAS (ALL, AML, CML, MDS)               33,6%
Page 3: Lymphoproliferative diseases  (44,9%) LEUKEMIAS (ALL, AML, CML, MDS)               33,6%
Page 4: Lymphoproliferative diseases  (44,9%) LEUKEMIAS (ALL, AML, CML, MDS)               33,6%

Treatment results of solid tumours in childrenTreatment results of solid tumours in children

CNS TUMOURSCNS TUMOURS 60% 60%• NEPHROBLASTOMANEPHROBLASTOMA 80% 80%• NEUROBLASTOMANEUROBLASTOMA 45% 45%• SOFT TISSUE SARCOMASSOFT TISSUE SARCOMAS 43% 43%• BONE TUMOURSBONE TUMOURS 57% 57%• RETINOBLASTOMARETINOBLASTOMA 70% 70%• EMBRIONAL TUMOURSEMBRIONAL TUMOURS 85% 85%

Page 5: Lymphoproliferative diseases  (44,9%) LEUKEMIAS (ALL, AML, CML, MDS)               33,6%

Brain tumors comprise approximately 20% of all childhood malignancies, second only to acute lymphoblastic leukemia in frequency.

Page 6: Lymphoproliferative diseases  (44,9%) LEUKEMIAS (ALL, AML, CML, MDS)               33,6%

Astrocytoma is the most common brain tumor, accounting for more than half of all primary central nervous system (CNS) malignancies.

It can be distinguished: pilocytic astrocytoma (WHO grade I)diffuse astrocytoma (WHO grade II)anaplastic astrocytoma (WHO grade III)glioblastoma multiforme (WHO grade IV)

Page 7: Lymphoproliferative diseases  (44,9%) LEUKEMIAS (ALL, AML, CML, MDS)               33,6%

This MRI shows a supratentorial glioblastoma multiforme

This MRI shows a juvenile pilocytic astrocytoma of the

cerebellum

Page 8: Lymphoproliferative diseases  (44,9%) LEUKEMIAS (ALL, AML, CML, MDS)               33,6%

Medulloblastoma is the most common malignant brain tumor in children, accounting for 10-20% of primary central nervous system (CNS) neoplasms and approximately 40% of all posterior fossa tumors.

It is a highly invasive embryonal neuroepithelial tumor that arises in the cerebellum and has a tendency to disseminate throughout the CNS early in its course.

MRI showing a medulloblastoma

of the cerebellum

Page 9: Lymphoproliferative diseases  (44,9%) LEUKEMIAS (ALL, AML, CML, MDS)               33,6%

MRI showing an ependymoma of the fourth ventricle, compressing the cerebellum and brain stem

Ependymoma is the third most common brain tumor in children, accounting for approximately 10% of primary central nervous system (CNS) neoplasms.

It is a neuroepithelial tumor that arises within, or adjacent to, the ependymal lining of the ventricular system or the central canal of the spinal cord. It tends to invade locally, even if histological appearance is benign.

Approximately 90% of tumors are intracranial, with up to 70% occurring in the posterior fossa.

Page 10: Lymphoproliferative diseases  (44,9%) LEUKEMIAS (ALL, AML, CML, MDS)               33,6%

RETINOBLASTOMA• Most cells comprising the tumor

histologically resembled the cells of an undifferentiated retina of the embryo called retinoblasts.

• The most widely held concept of histogenesis of retinoblastoma holds that it generally arises from a multipotential precursor cell (mutation in the long arm of chromosome 13 band 13q14) that could develop into almost any type of inner or outer retinal cell.

Worldwide, the incidence of retinoblastoma is recorded to be about 11 cases per million children younger than 5 years.

Page 11: Lymphoproliferative diseases  (44,9%) LEUKEMIAS (ALL, AML, CML, MDS)               33,6%

• Retinoblastoma is diagnosed at an average of 18 months with 90% diagnosed before patients reach age 5 years.

• Children who are affected bilaterally are diagnosed at an average age of 13 months, while patients with unilateral retinoblastoma are diagnosed at an average age of 24 months.

• When a known family history of retinoblastoma exists, patients with bilateral retinoblastoma are diagnosed at an average age of 11 months.

Page 12: Lymphoproliferative diseases  (44,9%) LEUKEMIAS (ALL, AML, CML, MDS)               33,6%

• Leukocoria (white pupillary reflex or cat's eye reflex) is the most common presenting sign, accounting for about 56.1% of cases.

• Strabismus, which occurs as a result of visual loss, is the second most common mode of presentation. Thus, funduscopic examination through a well-dilated pupil must be performed in all cases of childhood strabismus.

• Retinoblastoma can cause secondary changes in the eye, including glaucoma, retinal detachment, and inflammation secondary to tumor necrosis.

– Pseudouveitis, with a red eye and pain associated hypopyon and hyphema, is a rare presentation. It is characteristic of an infiltrating type of retinoblastoma in which the tumor cells invade the retina diffusely without forming a discrete tumor mass.

– Orbital inflammation mimicking orbital cellulitis may occur in eyes with necrotic tumors and does not necessarily imply extraocular extension.

• Proptosis is a more common presenting symptom in most underdeveloped countries.

Page 13: Lymphoproliferative diseases  (44,9%) LEUKEMIAS (ALL, AML, CML, MDS)               33,6%

– EBRT is still indicated in selected circumstances:

• For eyes with significant vitreous seeding

• For children who have progression of disease while undergoing chemoreduction

• For tumors extending up to or beyond the cut margin of the optic nerve of an enucleated eye

• Radioactive isotope plaques– Use of either radioactive 60 Co

(cobalt), radioactive 125 I (iodine), which is presently the most used, radioactive 192 Ir (iridium), and radioactive 106 Ru (ruthenium)

– Radioactive 125 I plaque treatment is recommended for treatment of one larger tumor or a limited number of moderately sized tumors (<3) present in noncritical areas

– Advantage - Locally directed treatment to the tumor minimizing radiation to the normal tissue

– Disadvantage - Incomplete treatment, high dose to local sclera, significantly less irradiation for anterior lesions, and difficulty placing posterior plaques

Page 14: Lymphoproliferative diseases  (44,9%) LEUKEMIAS (ALL, AML, CML, MDS)               33,6%

• Enucleation– Enucleation is performed when there is no chance of preserving useful vision in an eye. – Patients generally requiring enucleation are those who present with total retinal

detachments and/or the posterior segment is full of the tumor in which case it is clear the patient cannot retain any form of useful vision.

• Cryotherapy– Cryotherapy can be used primarily for small anteriorly located tumors, remote from the

disc and macula but also may be indicated for recurrence after radiation therapy. – Cryotherapy is performed transsclerally. Under direct visualization, freezing is carried out

until the ice ball incorporates the entire tumor. A refreeze-thaw cycle is repeated 3-4 times. – Complete disappearance of the tumor with a flat pigmented scar is the sign of successful

treatment. This can be repeated if the tumor does not respond initially.

• Photocoagulation– Photocoagulation can be used as primary therapy for small posteriorly located tumors. – There is a danger of producing large field defects near the disc and decreased vision

resulting from macular pucker by photocoagulation near the macula. – The technique is performed by placing a double row of confluent burns around each tumor

using a photocoagulator. – It is important not to do direct treatment on the tumor itself because the light color of the

tumor generally precludes absorption of sufficient energy and there is a danger of exploding the tumor with spread of viable tumor debris into the vitreous and other parts of the retina.

– Successful treatment with photocoagulation takes weeks to evolve, which is a complete disappearance of the tumor and replaced with a flat area.

– Photocoagulation also can be used for tumor recurrences after EBRT.

Page 15: Lymphoproliferative diseases  (44,9%) LEUKEMIAS (ALL, AML, CML, MDS)               33,6%

Objawy kliniczne• Endophytic growth occurs when the tumor

breaks through the internal limiting membrane and has an ophthalmic appearance of a white-to-cream mass showing either no surface vessels or small irregular tumor vessels. This growth pattern typically is associated with vitreous seeding wherein small fragments of tissue become separated from the main tumor.

• Exophytic growth occurs in the subretinal space. This growth pattern often is associated with subretinal fluid accumulation and retinal detachment.

• Diffuse infiltrating growth is a rare subtype comprising 1.5% of all retinoblastoma. It is characterized by a relatively flat infiltration of the retina by tumor cells but without a discrete tumor mass.

Page 16: Lymphoproliferative diseases  (44,9%) LEUKEMIAS (ALL, AML, CML, MDS)               33,6%
Page 17: Lymphoproliferative diseases  (44,9%) LEUKEMIAS (ALL, AML, CML, MDS)               33,6%

NephroblastomaNephroblastoma• third most common solid tumour (6-9 cases/ 1

million children)• location

– in one kidney (90-95%)– in both kidneys (5-10%)– hereditary tumours (7-10%)

• WT1 gene (11p13), WT2 gene (11p15), WT3 gene (?)

Page 18: Lymphoproliferative diseases  (44,9%) LEUKEMIAS (ALL, AML, CML, MDS)               33,6%

• The most common presentation of Wilms tumor is the presence of an asymptomatic abdominal mass.

• Hypertension, gross hematuria, and fever are observed in 5-30% of patients.

• A small number of patients who have hemorrhaged into their tumor may present with signs of hypotension, anemia, and fever.

• Rarely, patients with advanced-stage disease may present with respiratory symptoms related to the presence of lung metastases.

Page 20: Lymphoproliferative diseases  (44,9%) LEUKEMIAS (ALL, AML, CML, MDS)               33,6%

NephroblastomaNephroblastoma• clinical staging : SIOP system

and NWTS (stages I-V)

• histological classification according to Beckwith and Palmer – blastomatous element

– epithelial (tubular) elements

– mesenchymal elements

Page 21: Lymphoproliferative diseases  (44,9%) LEUKEMIAS (ALL, AML, CML, MDS)               33,6%

Stage, Histology Surgery Chemotherapy Radiotherapy*

Stage I or II with FHStage I with anaplasia

NephrectomyVincristineDactinomycin

None

Stage III or IV with FHStage II, III, or IV with focal anaplasia

NephrectomyVincristineDactinomycinDoxorubicin

Yes

Stage II, III, or IV with diffuse anaplasiaStage I, II, III, or IV CCSK

Nephrectomy

VincristineDoxorubicinCyclophosphamideEtoposide

Yes

Stage I, II, III, or IV RTK

NephrectomyCyclophosphamideEtoposideCarboplatin

Yes

Page 22: Lymphoproliferative diseases  (44,9%) LEUKEMIAS (ALL, AML, CML, MDS)               33,6%

--large tongue (macroglossia)large tongue (macroglossia)-large organs (visceromegaly)-large organs (visceromegaly)-large body size (macrosomia)-large body size (macrosomia)-hernia of the navel-hernia of the navel-small head (microcephaly)-small head (microcephaly)-Wilms’ tumour-Wilms’ tumour

Cytogenetics studies:

An 11p13 deletion as in the WAGR syndrome (Wilms, aniridia, genitourinary abnormalities, mental retardation)

A duplication of the paternal allele 11p15 as in BWS

Mutational analysis of the WT1 gene in cases where Denys-Drash syndrome (intersexual disorders, nephropathy, Wilms tumor) is suspected

Page 23: Lymphoproliferative diseases  (44,9%) LEUKEMIAS (ALL, AML, CML, MDS)               33,6%

NeuroblastomaNeuroblastoma• second most common solid tumour (1 case/ 10000

children)• location

– retroperineum (75-80%)

– posterior mediastinum (20%)

– cervical ganglia (5%)

• clinical appearance depends on the origin of the tumor, metastasis and hormonally active metabolic products

Page 24: Lymphoproliferative diseases  (44,9%) LEUKEMIAS (ALL, AML, CML, MDS)               33,6%

• Age, stage, and some molecular defects encountered in tumor cells are important prognostic factors and are used for risk-stratification and treatment assignment.

• The differences in outcome for patients with neuroblastoma are striking. Infants younger than 1 year have a good prognosis, even in the presence of metastatic disease, whereas older patients with metastatic disease fare poorly, even when treated with aggressive therapy.

• Unfortunately, approximately 70-80% of patients older than 1 year present with metastatic disease, usually to lymph nodes, liver, bone, and bone marrow.

Page 25: Lymphoproliferative diseases  (44,9%) LEUKEMIAS (ALL, AML, CML, MDS)               33,6%

• More than 90% of patients have elevated homovanillic acid (HVA) and/or vanillylmandelic acid (VMA) detectable in urine.

• Mass screening studies using urinary catecholamines in neonates and infants in Japan, Quebec, and Europe have demonstrated the ability to detect neuroblastoma before it clinically is apparent. However, most of the tumors identified using this method occur in infants who have a good prognosis. No data exist to suggest that mass screening has decreased deaths from high-risk neuroblastoma.

• Markers associated with a poor prognosis are elevated ferritin, serum lactate dehydrogenase (LDH), and serum neuron-specific enolase (NSE).

Page 26: Lymphoproliferative diseases  (44,9%) LEUKEMIAS (ALL, AML, CML, MDS)               33,6%

MRI of a left adrenal mass. The mass was detected by fetal ultrasound at 30 weeks of gestation. During infancy, the mass was found on the inferior pole of the left adrenal and was completely resected. Before surgery, the metastatic workup was negative. Surgical pathology service confirmed a diagnosis of neuroblastoma. After 3 years of follow-up care, no recurrence was observed.

Page 27: Lymphoproliferative diseases  (44,9%) LEUKEMIAS (ALL, AML, CML, MDS)               33,6%

A one-week-old neonate had an abdominal ultrasound for evaluation of projectile vomiting. A right adrenal mass (100% cystic) was an

incidental finding. Evaluation of the mass by CT was consistent with an adrenal bleed (3.6 x 3.1 x 2.4 cc). The infant was followed at 2 weeks (2D size diminished to 1.5 x. 2.4 cm sq. by Ultrasound) and then at 6 weeks to document that the adrenal bleed continued to

involute. Urine catecholamines were normal.

Page 28: Lymphoproliferative diseases  (44,9%) LEUKEMIAS (ALL, AML, CML, MDS)               33,6%

• Symptoms include abdominal pain, emesis, weight loss, anorexia, fatigue, bone pain, and chronic diarrhea. Hypertension is an uncommon sign of the disease and generally is caused by renal artery compression, not catecholamine excess.

• Because more than 50% of patients present with advanced-stage disease, usually to the bone and bone marrow, the most common presentation includes bone pain and a limp. However, patients also may present with unexplained fever, weight loss, irritability, and periorbital ecchymosis secondary to metastatic disease to the orbits. The presence of bone metastases can lead to pathologic fractures.

• Approximately two thirds of patients with neuroblastoma have abdominal primaries. In these circumstances, patients can present with an asymptomatic abdominal mass that usually is discovered by the parents or a caregiver.

• Symptoms produced by the presence of the mass depend on its proximity to vital structures and usually progress over time.

– Tumors arising from the paraspinal sympathetic ganglia can grow through the spinal foramina into the spinal canal and impinge on the spinal cord. This may result in the presence of neurologic symptoms, including weakness, limping, paralysis, and even bladder and bowel dysfunction.

– Thoracic neuroblastomas (posterior mediastinum) may be asymptomatic and usually are diagnosed by imaging studies obtained for other reasons. Presenting signs or symptoms may be insignificant and involve mild airway obstruction or chronic cough, leading to a chest radiograph.

– Thoracic tumors extending to the neck can produce Horner syndrome. Primary cervical neuroblastoma is rare but should be considered in the differential diagnosis of masses of the neck, especially in infants younger than 1 year with feeding or respiratory difficulties.

Page 29: Lymphoproliferative diseases  (44,9%) LEUKEMIAS (ALL, AML, CML, MDS)               33,6%

NeuroblastomaNeuroblastoma• clinical staging : Evans’

system and INNS (International Neuroblastoma Saging system)

• histological staging according to Hughes’ or Shimada’s classification

Page 30: Lymphoproliferative diseases  (44,9%) LEUKEMIAS (ALL, AML, CML, MDS)               33,6%

• N-MYC, RAS amplification and N-MYC, RAS amplification and expressionexpression

• 1p deletion1p deletion

• 17q17q

• 11q, 14q deletion11q, 14q deletion

• Exspression of Exspression of TRKA, TRKB, TRKA, TRKB, TRKCTRKC (receptor for neurotropins) (receptor for neurotropins)

Page 31: Lymphoproliferative diseases  (44,9%) LEUKEMIAS (ALL, AML, CML, MDS)               33,6%
Page 32: Lymphoproliferative diseases  (44,9%) LEUKEMIAS (ALL, AML, CML, MDS)               33,6%
Page 33: Lymphoproliferative diseases  (44,9%) LEUKEMIAS (ALL, AML, CML, MDS)               33,6%

Liver tumoursLiver tumours• Hepatoblastoma

– usually occurs in children under 5 years of age

• hepatocellular carcinoma– usually occurs in older children

– the cause of cancer : chronic liver disease, viral hepatitis, hemochromatosis, mycotoxins

• AFP serum level - indicator– whether the disease is responding to

treatment

– whether the disease is come back

Page 34: Lymphoproliferative diseases  (44,9%) LEUKEMIAS (ALL, AML, CML, MDS)               33,6%

• Hepatoblastoma usually is diagnosed as an asymptomatic abdominal mass.

• Approximately 10% of patients have incidental findings of hemihypertrophy.

• Hepatoblastoma can be associated with isosexual precocity. Penile and testicular enlargement without pubic hair is seen in patients with tumors that secrete the b subunit of human chorionic gonadotropin (b-hCG).

• HCC usually presents as a slowly enlarging, right, upper-quadrant mass that may be found during a routine physical examination, brought to medical attention by the patient, or discovered by the patient's parents.

• Many children also experience localized pain, nausea, vomiting, and weight loss. Nearly 25% of patients present with jaundice.

• In adults, chronic hepatitis secondary to alcohol exposure, infection with hepatitis, and hereditary hemochromatosis are predisposing factors. Aflatoxins and other environmental factors also are likely to play a role in the pathogenesis in adults. In comparison, children are far more likely to have inherited errors of metabolism, such as tyrosinemia or urea cycle enzymopathies. Liver diseases that cause cirrhosis increase risk for developing HCC.

• Children with biliary atresia, chronic cholestasis, or glycogen storage diseases are at increased risk.

• Symptoms can be masked in children with preexisting hepatic diseases, and, accordingly, a change in a chronic disease pattern merits careful consideration for the possibility of a new malignancy.

Page 35: Lymphoproliferative diseases  (44,9%) LEUKEMIAS (ALL, AML, CML, MDS)               33,6%

Computed tomogram of hepatoblastoma

Computed tomogram of large

hepatocellular carcinoma

Page 36: Lymphoproliferative diseases  (44,9%) LEUKEMIAS (ALL, AML, CML, MDS)               33,6%

OsteosarcomaOsteosarcoma• usually associated with the period of rapid growth in usually associated with the period of rapid growth in

adolescenceadolescence• most common malignant bone tumour in childrenmost common malignant bone tumour in children• Rb gene is associated with osteosarcomaRb gene is associated with osteosarcoma• tumour tends to occure in the femur (distal end), tumour tends to occure in the femur (distal end),

humerus (proximal end) and tibia (proximal end)humerus (proximal end) and tibia (proximal end)– can occur in any bonecan occur in any bone

Page 37: Lymphoproliferative diseases  (44,9%) LEUKEMIAS (ALL, AML, CML, MDS)               33,6%
Page 38: Lymphoproliferative diseases  (44,9%) LEUKEMIAS (ALL, AML, CML, MDS)               33,6%

MRI of the same distal femoral osteosarcoma

Lateral plain radiograph of the knee shows an osteosarcoma of the distal femur. The lesion is mainly posterior, with disruption and elevation of the periosteum (Codman triangle), and extends beyond the bone into the soft tissue.

Page 39: Lymphoproliferative diseases  (44,9%) LEUKEMIAS (ALL, AML, CML, MDS)               33,6%

MRI of osteosarcomaMRI of osteosarcoma

Page 40: Lymphoproliferative diseases  (44,9%) LEUKEMIAS (ALL, AML, CML, MDS)               33,6%
Page 41: Lymphoproliferative diseases  (44,9%) LEUKEMIAS (ALL, AML, CML, MDS)               33,6%

OsteosarcomaOsteosarcoma

Page 42: Lymphoproliferative diseases  (44,9%) LEUKEMIAS (ALL, AML, CML, MDS)               33,6%

OsteosarcomaOsteosarcoma

Page 43: Lymphoproliferative diseases  (44,9%) LEUKEMIAS (ALL, AML, CML, MDS)               33,6%

MRI osteosarcomaMRI osteosarcoma

Page 44: Lymphoproliferative diseases  (44,9%) LEUKEMIAS (ALL, AML, CML, MDS)               33,6%

Ewing’s sarcomaEwing’s sarcoma• usually associated with the period of rapid growth in usually associated with the period of rapid growth in

adolescenceadolescence• tumour tends to occure in the long bones of the tumour tends to occure in the long bones of the

extremities, the pelvis or the chestextremities, the pelvis or the chest– may occur in the skull or flat bones of the trunkmay occur in the skull or flat bones of the trunk

– can occur in any bonecan occur in any bone

• the tumour spreads easily, often to lungs and other the tumour spreads easily, often to lungs and other bones (metastases present in 1/3 of the children at the bones (metastases present in 1/3 of the children at the time of diagnosis)time of diagnosis)

Page 45: Lymphoproliferative diseases  (44,9%) LEUKEMIAS (ALL, AML, CML, MDS)               33,6%

Ewing’ sarcomaEwing’ sarcoma

Page 46: Lymphoproliferative diseases  (44,9%) LEUKEMIAS (ALL, AML, CML, MDS)               33,6%

Ewing’ sarcomaEwing’ sarcoma

Page 47: Lymphoproliferative diseases  (44,9%) LEUKEMIAS (ALL, AML, CML, MDS)               33,6%

Rotationplasty in th epatient with Rotationplasty in th epatient with osteosarcoma of the distal femurosteosarcoma of the distal femur

Page 48: Lymphoproliferative diseases  (44,9%) LEUKEMIAS (ALL, AML, CML, MDS)               33,6%

Embrional tumours

Page 49: Lymphoproliferative diseases  (44,9%) LEUKEMIAS (ALL, AML, CML, MDS)               33,6%

• 1. TERATOMA

• 2. GERMINOMA (dysgerminoma and seminoma)

• 3. CARCINOMA EMBRYONALE

• 4. YOLK SAC TUMOR

• 5. CHORIOCARCINOMA

• 6. POLYEMBRYOMA

• 7. GONADOBLASTOMA

Page 50: Lymphoproliferative diseases  (44,9%) LEUKEMIAS (ALL, AML, CML, MDS)               33,6%

• Germ cell tumors account for 95% of testicular tumors and include seminomas, teratomas, choriocarcinomas, and mixed tumors.

• Seminomas comprise approximately 50% of all germ cell tumors. Seminomas are generally believed to arise from the germinal epithelium of the seminiferous tubules because "seminoma cells" are morphologically similar to spermatogonia and also because seminomas are frequently found within the seminiferous tubules in early stages.

Page 51: Lymphoproliferative diseases  (44,9%) LEUKEMIAS (ALL, AML, CML, MDS)               33,6%

• Gonadoblastoma is a rare benign tumor that has the potential for malignant transformation and affects a subset of patients with intersex disorders.

• The select intersex syndromes associated with a clear risk of developing gonadoblastoma are

– (1) complete androgen insensitivity/male pseudohermaphroditism (46,XY)

– (2) mixed gonadal dysgenesis (45,X/46,XY)

– (3) a subset of patients with Turner syndrome (45,XO).

• The 2 essential findings that predispose these abnormal gonads to undergo neoplastic transformation into gonadoblastoma are

– (1) the karyotype has either macroscopic or molecular evidence of a Y chromosome

– (2) the gonads nearly always are located intra-abdominally.

Page 52: Lymphoproliferative diseases  (44,9%) LEUKEMIAS (ALL, AML, CML, MDS)               33,6%

• Soft tissue sarcomas, the fifth most common solid tumor in children, are relatively rare, comprising about 6-7% of childhood malignancies.

• Rhabdomyosarcomas account for about half of these tumors; nonrhabdomyosarcoma

soft tissue sarcomas (NRSTS) account for the remainder (ie, about 3% of childhood malignancies).

• NRSTS are a heterogenous set of tumors, sharing some biologic characteristics but differing in histology. The most common types are – synovial cell sarcomas– malignant fibrous histiocytomas– fibrosarcomas– malignant peripheral nerve sheath tumors– hemangiopericytomas– alveolar soft part sarcomas– leiomyosarcomas– liposarcomas– desmoplastic small cell tumors

Page 53: Lymphoproliferative diseases  (44,9%) LEUKEMIAS (ALL, AML, CML, MDS)               33,6%

Rhabdomyosarcoma (RMS) (from Greek, rhabdo, meaning rod shape, and

myo, meaning muscle)

• Several distinct histologic groups have prognostic significance, including – embryonal RMS (ERMS, which occurs in 55% of

patients)

– botryoid variant of ERMS (5% of patients)

– alveolar RMS (ARMS, 20% of patients)

– undifferentiated sarcoma (UDS, 20% of patients)

Page 54: Lymphoproliferative diseases  (44,9%) LEUKEMIAS (ALL, AML, CML, MDS)               33,6%

Although the tumor is believed to arise from primitive muscle cells, tumors can occur anywhere in the body except bone.

The most common sites are the head and neck (28%), extremities (24%), and genitourinary (GU) tract (18%). Other notable sites include the trunk (11%), orbit (7%), and retroperitoneum (6%). RMS occurs at other sites in <3% of patients.

The botryoid variant of ERMS arises in mucosal cavities, such as the bladder, vagina, nasopharynx, and middle ear. Lesions in the extremities are most likely to have an alveolar type of histology.

Metastases are found predominantly in the lungs, bone marrow, bones, lymph nodes, breasts, and brain.

Page 55: Lymphoproliferative diseases  (44,9%) LEUKEMIAS (ALL, AML, CML, MDS)               33,6%

Typical presentations by the location of nonmetastatic disease are as follows:

Orbit - Proptosis or dysconjugate gazeParatesticular - Painless scrotal massProstate - Bladder or bowel difficultiesUterus, cervix, bladder - Menorrhagia or metrorrhagiaVagina - Protruding polypoid mass (botryoid, meaning a grapelike cluster)Extremity - Painless massParameningeal (ear, mastoid, nasal cavity, paranasal sinuses, infratemporal fossa, pterygopalatine fossa) - Upper respiratory symptoms or pain